Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule with the chemical formula C14H12N4S and a molecular weight of approximately 268.34 g/mol. It is an experimental compound that has been studied primarily as an inhibitor of dihydrofolate reductase (DHFR), a key enzyme in folate metabolism essential for de novo glycine and purine synthesis and DNA precursor synthesis. The drug has not been approved for any indication and is not known to be in active clinical development or marketed anywhere[1][2][6]. Its primary mechanism involves targeting DHFR; however, it may also interact with other related enzymes based on protein binding data[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-phenylsulfanyl-2,4-quinazolinediamine.